Europace Advance Access originally published online on January 16, 2009
Europace 2009 11(3):379-381; doi:10.1093/europace/eun378
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SHORT COMMUNICATIONS
Sporadic arrhythmogenic right ventricular cardiomyopathy/dysplasia due to a de novo mutation
1 Département de Cardiologie, Hôpital Pitié-Salpêtrière, AP-HP, 47-83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France; 2 INSERM, UMR-S621, AP-HP, UPMC Université Paris 6, 91 Boulevard de l'Hôpital, 75013 Paris, France; 3 Service de Biochimie, Unité de Cardiogénétique et Myogénétique, Hôpital Pitié-Salpêtrière, AP-HP, 47-83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France; 4 Centre de Cardiologie, Centre Hospitalier Universitaire, 2-10 Boulevard Maréchal de Lattre de Tassigny BP77908, 21079 Dijon, Cedex, France; 5 Centre de Génétique, Centre Hospitalier Universitaire, 2-10 Boulevard Maréchal de Lattre de Tassigny BP77908, 21079 Dijon, Cedex, France; 6 INSERM U582, Hôpital Pitié-Salpêtrière, AP-HP, 47-83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France; 7 Département de Génétique, Hôpital Pitié-Salpêtrière, AP-HP, 47-83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France
We report the case of a 41-year-old man with a diagnosis of sporadic arrhythmogenic right ventricular cardiomyopathy (ARVC). Genetic screening identified the heterozygous missense mutation R49H in the desmoglein-2 gene. The mutation was absent in both parents, and we demonstrated that it was a de novo mutation. To the best of our knowledge, this is the first description of a de novo mutation in ARVC. This has important implications, including for clinical practice, since individuals with sporadic ARVC caused by a de novo mutation can transmit the disease gene to 50% of their offspring. This suggests that the benefit of molecular genetics can be extended to sporadic ARVC and may improve genetic counselling.
* Corresponding author: Département de Génétique, Bâtiment Pinel, CHU Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, 75013 Paris, France, Tel: +33 1 42 16 13 47, Fax: +33 1 42 16 13 64, Email: philippe.charron{at}psl.aphp.fr
Manuscript submitted 10 October 2008. Accepted after revision 8 December 2008.